{
    "clinical_study": {
        "@rank": "152874", 
        "arm_group": {
            "arm_group_label": "PRLX 93936", 
            "arm_group_type": "Experimental", 
            "description": "PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle"
        }, 
        "brief_summary": {
            "textblock": "To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for\n      patients with relapsed or relapsed/refractory multiple myeloma."
        }, 
        "brief_title": "Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of\n           PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks\n           followed by a 9 day rest period, as treatment for patients with relapsed or\n           relapsed/refractory multiple myeloma.\n\n        -  To establish the dose of PRLX 93936 recommended for future studies.\n\n        -  To characterize potential toxicities of PRLX 93936.\n\n        -  To assess the pharmacokinetic profile of PRLX 93936.\n\n        -  To evaluate response to treatment, time to response (TTR) and duration of response.\n\n        -  To evaluate time to progression (TTP)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have a diagnosis of multiple myeloma and have relapsed or\n             relapsed/refractory disease.\n\n          -  Patient must have received \u2265 2 prior anti-myeloma regimens including a proteasome\n             inhibitor and/or immunomodulatory agent.\n\n          -  Patient currently requires systemic therapy.\n\n          -  Patient has measurable disease.\n\n          -  Age \u2265 18 years\n\n          -  Karnofsky performance status \u2265 60%\n\n          -  ECOG performance 0, 1 or 2\n\n          -  Life expectancy of at least three months\n\n          -  Able to take acetaminophen\n\n          -  Not pregnant\n\n          -  Patient must have recovered from toxicities incurred as a result of any previous\n             anti-myeloma therapy or recovered to baseline.\n\n          -  Patients who received an autologous stem cell transplant must be \u2265 3 months\n             post-transplant and all associated toxicities must have resolved to \u2264 CTCAE Grade 1.\n\n          -  QT intervals of QTc \u2264 500 msec\n\n        Exclusion Criteria:\n\n          -  POEMS syndrome\n\n          -  Plasma cell leukemia\n\n          -  Primary amyloidosis\n\n          -  Patient has smoldering multiple myeloma or monoclonal gammopathy of unknown\n             significance (MGUS).\n\n          -  Evidence of spinal cord compression or CNS complication unless controlled by\n             appropriate therapy.\n\n          -  Patient received chemotherapy or other anti-cancer therapy that may be active against\n             multiple myeloma within 3 weeks prior to the first dose of PRLX 93936.\n\n          -  Patient received nitrosureas within 6 weeks prior to the first dose.\n\n          -  Patient received corticosteroids within 2 weeks prior to the first dose.\n\n          -  Patient received plasmapheresis within 4 weeks prior to the first dose.\n\n          -  Patient  had  major  surgery  within  4  weeks  prior  to  the  first  dose.\n\n          -  Patient had an allogeneic stem cell transplant within 6 months before first dose of\n             PRLX 93936 or has evidence of graft versus host disease.\n\n          -  Patient is taking any therapy concomitantly that may be active against multiple\n             myeloma.\n\n          -  Patient  is  currently  receiving  medication(s)  that  are  principally  metabolized\n              via  the cytochrome P450 3A4 enzyme pathway.\n\n          -  Use of any investigational agents within 28 days or 5 half-lives (whichever is\n             shorter) of study treatment.\n\n          -  Patient has peripheral neuropathy of Grade 3 or greater intensity, or painful Grade\n             2, as defined by the NCI CTC.\n\n          -  Patient had a myocardial infarction within 6 months of enrollment or has NYHA Class\n             III or IV heart failure uncontrolled angina, severe uncontrolled ventricular\n             arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction\n             system abnormalities.\n\n          -  Abnormal LVEF (< LLN for the institution for a patient of that age) on echocardiogram\n\n          -  Patient has poorly controlled hypertension, diabetes mellitus, or other serious\n             medical or psychiatric illness that could potentially interfere with the completion\n             of treatment according to protocol.\n\n          -  Patient had a malignancy other than multiple myeloma within 3 years before\n             enrollment, with the exception of adequately treated basal cell or squamous cell skin\n             cancer, in situ cervical cancer, in situ breast cancer, or in situ prostate cancer.\n\n          -  Patient's clinical laboratory values meet any of the following criteria within the 7\n             days prior to Study Day 1:\n\n               -  Bilirubin > 1.5 times ULN\n\n               -  AST (SGOT), ALT (SGPT) and Alkaline phosphatase > 2.5 times ULN\n\n               -  Uncontrolled hypercalcemia (defined as serum calcium > 14 mg/dL)\n\n               -  Serum creatinine > 2.0 mg/dL or creatinine clearance of < 30 mL/min\n\n               -  ANC < 1000 cells/mm3 or < 750 cells/mm3 due to >50% marrow involvement\n\n               -  Platelet count < 50,000 cells/mm3\n\n               -  Hemoglobin < 8.0 g/dL\n\n          -  Patient is known to be human immunodeficiency virus (HIV)-positive.\n\n          -  Patient is known to be hepatitis B surface antigen-positive or has known active\n             hepatitis C infection.\n\n          -  Patient has an active systemic infection requiring treatment or within 14 days before\n             first dose of PRLX 93936.\n\n          -  Pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695590", 
            "org_study_id": "PRLX93936-0002"
        }, 
        "intervention": {
            "arm_group_label": "PRLX 93936", 
            "description": "PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered", 
            "intervention_name": "PRLX 93936", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myeloma", 
            "PRLX93936"
        ], 
        "lastchanged_date": "May 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "amyl_destefanis@dfci.harvard.edu", 
                    "last_name": "Amy Destefanis", 
                    "phone": "617-632-6752"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Robert Schlossman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "barbara_riff@med.unc.edu", 
                    "last_name": "Barbara Riff", 
                    "phone": "919-843-7046"
                }, 
                "contact_backup": {
                    "email": "katherine_mckernan@med.unc.edu", 
                    "last_name": "Katherine McKernan", 
                    "phone": "919-966-4432"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina at Chapel Hill"
                }, 
                "investigator": {
                    "last_name": "Peter Voorhees, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberly.bartlett@duke.edu", 
                    "last_name": "Kimberly Oates", 
                    "phone": "919-668-6524"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Cristina Gasparetto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sue.ogara@uc.edu", 
                    "last_name": "Sue O'Gara", 
                    "phone": "513-604-3982"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "investigator": {
                    "last_name": "John Morris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cindy.farley@scresearch.net", 
                    "last_name": "Cindy Farley", 
                    "phone": "615-329-7237"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Jesus G. Berdeja, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Paul Richardson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 (28 days from first dose)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695590"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response to treatment", 
                "safety_issue": "No", 
                "time_frame": "Each cycle (assessed every 28 days starting from first dose, for up to 8 months)"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "From date of first dose to date of response, assessed up to 8 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "From date of response to first documented progression or death, or date last known progression-free and alive at study discontinuation, assessed up to 8 months"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "From date of first dose to first documented progression, assessed up to 8 months"
            }
        ], 
        "source": "Prolexys Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prolexys Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}